United States: New FDA Final Rule On Abbreviated New Drug Applications And 505(B)(2) Applications: What You Need To Know
Last Updated: November 3 2016

On December 5, 2016, the FDA's newest final rule on ANDAs and 505(b)(2) applications will become effective. This presentation will make sure you stay up to date on the changes to the FDA's regulations, especially as they may impact Hatch-Waxman Act litigations. Topics will include:

  • Changes to Orange Book listings and procedures, including use codes, expansion of the category of "untimely filed patent information," and challenges to listed patent information;
  • Changes to Paragraph IV Certifications, including new limitations on the timeframe in which notice can be provided, and revisions to the content of the Certifications may be made;
  • The FDA's new requirement for 505(b)(2) applications, which is designed to ensure that such applications don't circumvent patent certification obligations.

Register:
There is no charge to attend this program. Please register by Wednesday, November 9, 2016. Webinar access and dial-in information will be sent upon registration.

Scheduling Conflict? Finnegan records all hosted webinars. To view the recorded program, simply register for the webinar and you will receive an access link shortly after the live program is complete.

Register

Moderator:
Jonathan R. Davies, Ph.D.

Speakers:
Barbara R. Rudolph, Ph.D.
Robert C. Stanley

Date:
Thursday, November 10, 2016

Time:
10:00 - 11:00 a.m. PST
1:00 - 2:00 p.m. EST


To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By Rachel Emsley, Nathan I. North, Mark Feldstein
By Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
By Pier DeRoo
By Brian Kacedon, John Paul, Robert MacKichan III, M. David Weingarten
By Christopher Johns
By Brian Kacedon, John Paul, Sydney Kestle
By Brian Kacedon, John Paul, Nicholas Doyle
By M. David Weingarten, Kevin Rodkey
By Susan Tull
By Christine Lehman
Tools
Print
Font Size:
Translation
Channels